The S100A6 calcium-binding protein regulates endothelial cell-cycle progression and senescence

Endothelial Cell Biology Unit, School of Molecular & Cellular Biology, LIGHT Laboratories, University of Leeds, Clarendon Way, Leeds, LS2 9JT, UK.
FEBS Journal (Impact Factor: 4). 10/2012; 279(24). DOI: 10.1111/febs.12044
Source: PubMed


Endothelial cells regulate many aspects of vascular physiology including vasculogenesis and angiogenesis. The S100 family of calcium-binding protein regulates many aspects of cell function but their roles in vascular physiology are less well understood. Herein, we investigated the expression and function of S100-related family members in endothelial cells. Analysis of total endothelial mRNAs using a human gene chip array revealed significant gene expression of the S100 calcium-binding protein family members S100A6, S100A10, S100A11 and S100A13. We examined the expression and functional properties of the major S100 family member, S100A6, in vascular endothelial cells. Comparison of primary and transformed human cells revealed significant differences in S100A6 protein levels. In primary human endothelial cells, S100A6 was present in both the nucleus and cytoplasm. To assess the function of endothelial S100A6, we depleted protein levels using RNA interference and this caused increased cell cycle arrest in the G2/M phase under different conditions. S100A6 depletion caused a decrease in both CDK1 and phospho-CDK1 levels which are essential for eukaryote cell cycle progression. S100A6 depletion also decreased CDK1, cyclin A1 and cyclin B gene expression with effects on cell cycle progression. Depletion of endothelial S100A6 levels also elevated β-galactosidase expression which is an important hallmark of cellular senescence and exit from the mammalian cell cycle. We thus propose that S100A6 has an important role in regulating endothelial commitment to and progression through the cell cycle. © 2012 The Authors Journal compilation © 2012 FEBS.

Download full-text


Available from: Adam Odell, Dec 18, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pathogenesis of age-related macular degeneration (AMD), the leading cause of vision loss in the elderly, remains poorly understood due to the paucity of animal models that fully replicate the human disease. Recently, we showed that senescence-accelerated OXYS rats develop a retinopathy similar to human AMD. To identify alterations in response to normal aging and progression of AMD-like retinopathy, we compared gene expression profiles of retina from 3- and 18-mo-old OXYS and control Wistar rats by means of high-throughput RNA sequencing (RNA-Seq). We identified 160 and 146 age-regulated genes in Wistar and OXYS retinas, respectively. The majority of them are related to the immune system and extracellular matrix turnover. Only 24 age-regulated genes were common for the two strains, suggestive of different rates and mechanisms of aging. Over 600 genes showed significant differences in expression between the two strains. These genes are involved in disease-associated pathways such as immune response, inflammation, apoptosis, Ca ( 2+) homeostasis and oxidative stress. The altered expression for selected genes was confirmed by qRT-PCR analysis. To our knowledge, this study represents the first analysis of retinal transcriptome from young and old rats with biologic replicates generated by RNA-Seq technology. We can conclude that the development of AMD-like retinopathy in OXYS rats is associated with an imbalance in immune and inflammatory responses. Aging alters the expression profile of numerous genes in the retina, and the genetic background of OXYS rats has a profound impact on the development of AMD-like retinopathy.
    Cell cycle (Georgetown, Tex.) 05/2013; 12(11). DOI:10.4161/cc.24825 · 4.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) is a regulatory factor of the cell cycle. Its transcriptional activation and its protein stability are tightly controlled by several distinct mechanisms. S100A11 is a member of the S100 family of Ca(2+) -binding proteins involved in several biological processes including cell cycle progression and signal transduction. Here, we show that down-regulation of S100A11 results in the reduction of p21 protein in human HaCaT keratinocytes. It seems that a ubiquitin-independent proteasomal degradation process is involved in p21 degradation in S100A11 down-regulated cells. The application of a proteasome inhibitor stabilized p21 protein in these cells. Analyses of distinct signal transduction pathways revealed a disturbed phosphatidylinositol-3-kinase/Akt pathway after S100A11 knock-down. We determined that the glycogen synthase kinase-3, which is negatively regulated by PI3K/Akt, was activated in cells possessing knocked-down S100A11 and seems to be involved in p21 protein destabilization. The application of a specific inhibitor of GSK3 resulted in an increase of the p21 protein level in S100A11 down-regulated HaCaT cells. GSK3 is able to phosphorylate p21 at T57 that induces p21 proteasomal turnover. Mutation of the GSK3 site threonine-57 into alanine (T57A) stabilizes p21 in HaCaT cells lacking S100A11. Beside decreased p21 protein, down-regulation of S100A11 triggered the induction of apoptosis in HaCaT cells. These observations suggest that S100A11 is involved in maintenance of p21 protein stability and seems to function as an inhibitor of apoptosis in human HaCaT keratinocyte cells. Thus, the data shed light on a novel pathway regulating p21 protein stability. This article is protected by copyright. All rights reserved.
    FEBS Journal 06/2013; 280(16). DOI:10.1111/febs.12378 · 4.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: S100A6 is a calcium binding protein that, like some other members of the S100 protein family, is able to bind p53. This interaction may be physiologically relevant considering the numerous connotations of S100 proteins, and of S100A6 in particular, with cancer and metastasis. In this work we show that the interaction with S100A6 is limited to unmodified or phoshorylated p53 and is inhibited by p53 acetylation. Using in vitro acetylation assay we show that the presence of S100A6 attenuates p53 acetylation by p300. Furthermore, using ELISA, we show that S100A6 and the TAZ2 domain of p300 bind p53 with similar affinities and that S100A6 effectively competes with TAZ2 for binding to p53. Our results add another element to the complicated scheme of p53 activation.
    Journal of Molecular Biology 06/2013; 396(18). DOI:10.1016/j.jmb.2013.06.007 · 4.33 Impact Factor
Show more